Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.
about
Bacteria in Cancer Therapy: Renaissance of an Old ConceptTumor endothelial cellsRegional hyperthermia added to intensified preoperative chemo-radiation in locally advanced adenocarcinoma of middle and lower rectum.Polysilsesquioxane nanoparticles for triggered release of cisplatin and effective cancer chemoradiotherapyCustomizing systemic therapy in patients with advanced non-small cell lung cancer.Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy.VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.Targeted therapy in rectal cancer.Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy.Current status of antivascular therapy and targeted treatment in the clinic.Clinical biomarkers of angiogenesis inhibition.Multidisciplinary treatment of resectable rectal cancer.Tumor vasculature as target for therapeutic intervention.Jekyll and Hyde: the role of the microenvironment on the progression of cancer.Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis.The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.Treatment outcomes regarding the addition of targeted agents in the therapeutic portfolio for stage II-III rectal cancer undergoing neoadjuvant chemoradiation.
P2860
Q26751222-498C85E3-8237-4902-B263-58D8B82D7D39Q26995733-EE783BAA-F49F-42B0-B429-A0B62D309351Q34098024-9A5FCE22-C5CD-4743-8AE6-32DE72F11CADQ34791190-6005C8E8-CDA8-4F28-8990-2390D5A78449Q35146940-2400A278-B0D7-4B61-A4D1-00D5BDBC69F6Q35691033-A9A7BF7A-2481-4D24-9566-251CE600FA48Q36614764-A568D476-189E-43D4-89A7-7D9653038196Q36803200-A63FCCB3-8BBD-4DE9-9FC4-2486AE3453D4Q36935068-789D41E4-48EA-43D7-93DB-CDA683EC7233Q36957757-E23E0BF4-2ED2-4D19-BC8F-7FB159A92042Q36978021-769FF5EC-175A-4C90-9310-51F1FE1CDEA5Q37063510-5A9C2706-E4C2-4CD5-A3F4-BD2FB97DDEF2Q37139413-71D8A0ED-575B-40B0-83DF-3BE8E524CAA5Q37578503-4423E3DC-4CFC-4389-B77D-1EDEFC47A693Q37800110-FE016FE7-866A-4B6F-995E-CEBDDE253E3DQ37815128-B173A7F8-9A25-40B2-AE22-49C9075FDF56Q37995506-3FC3C0A4-D98D-46F1-9EEE-5CF81A438E9CQ46037079-34313961-A5FC-4C95-BD94-152AF8D8CB9AQ49381573-D093BD73-7E22-4A8D-A29B-BD9E3E3E882A
P2860
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Complete pathological response ...... ion in advanced rectal cancer.
@en
Complete pathological response ...... ion in advanced rectal cancer.
@nl
type
label
Complete pathological response ...... ion in advanced rectal cancer.
@en
Complete pathological response ...... ion in advanced rectal cancer.
@nl
prefLabel
Complete pathological response ...... ion in advanced rectal cancer.
@en
Complete pathological response ...... ion in advanced rectal cancer.
@nl
P2093
P2860
P356
P1476
Complete pathological response ...... ion in advanced rectal cancer.
@en
P2093
Brian G Czito
Christopher G Willett
Dan G Duda
Emmanuelle di Tomaso
Erik Paulson
Gordana Vlahovic
Gregory Y Lauwers
Herbert I Hurwitz
Johanna Bendell
Kenneth S Cohen
P2860
P304
P356
10.1038/NCPONC0813
P577
2007-05-01T00:00:00Z